BlossomHill Therapeutics shows clearly bullish insider buying and a positive but thinly sampled news-sentiment read, alongside a conservative balance sheet on leverage. Broader quality metrics remain flagged as a concern, with margin components at the bottom of their scale. No current share price is available this run, so no trade setup or risk/reward can be computed.
Thesis pillars
- Flagged Quality Concerns→Stable
- Clean Bullish Insider Buying→Stable
- Positive But Thin News Sentiment↑Improving
- +1 more pillar — see the Why tab for full reasoning
BlossomHill Therapeutics, Inc. (BLSM) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $22.27: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell... Read more
Sell if holding. Engine safety override at $22.27: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-09-09Recent Developments — BlossomHill Therapeutics, Inc.
Latest news
- NEWS LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32 — benzinga Sep 1, 2026 positive
- NEWS Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36 — benzinga Sep 1, 2026 positive
- NEWS JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28 — benzinga Sep 1, 2026 positive
- NEWS Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30 — benzinga Sep 1, 2026 positive
- NEWS This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday — benzinga Sep 1, 2026 positive
Generated 2026-09-09T18:02:14Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $22.27: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $20.71. Score 5.9/10, moderate confidence.
Take-profit target: $28.01 (+25.8% upside). Prior stop was $20.71. Stop-loss: $20.71.
Quality below floor (2.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin -39.6%), Material insider selling (20 sells, 0.93% of cap).
BlossomHill Therapeutics, Inc. trades at a P/E of N/A (forward -6.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
What does BlossomHill Therapeutics, Inc. do?BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that...
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.